{"id":7798,"date":"2026-02-24T06:08:28","date_gmt":"2026-02-24T06:08:28","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/igf-1-lr3\/"},"modified":"2026-04-09T14:26:04","modified_gmt":"2026-04-09T21:26:04","slug":"igf-1-lr3","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/igf-1-lr3\/","title":{"rendered":"IGF-1 LR3 \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to IGF-1 LR3 product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on IGF-1 LR3 \u2014 for educational purposes only<\/p>\n

\nIGF-1 LR3 IGFBP Binding Characteristics<\/summary>\n
\n

IGF-1 LR3 has markedly reduced affinity for IGF binding proteins (IGFBPs 1-6), which normally sequester >95% of circulating IGF-1. The Glu\u00b3\u2192Arg\u00b3 substitution disrupts a critical residue in the IGFBP binding domain, reducing IGFBP-3 affinity by approximately 1000-fold. The 13-amino-acid N-terminal extension further decreases IGFBP interaction. These modifications result in higher free IGF-1 concentrations when LR3 is used compared to equimolar native IGF-1, enhancing receptor occupancy and biological potency per unit mass.<\/p>\n

Francis GL et al. “Insulin-like growth factor 1 in a growth retardation syndrome.” Lancet.<\/em> 1992. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nIGF-1 Receptor Signaling: PI3K\/Akt and MAPK Pathways<\/summary>\n
\n

IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Ligand binding induces receptor autophosphorylation and recruitment of IRS-1\/2 adaptor proteins. This activates two major downstream cascades: (1) PI3K\/Akt pathway, promoting glucose uptake, protein synthesis (via mTOR), and cell survival; (2) Ras\/MAPK pathway, promoting cell proliferation. IGF-1 LR3 shows equivalent IGF-1R binding affinity and signaling potency to native IGF-1 despite the structural modifications, confirming that the IGFBP-binding domain is distinct from the receptor-binding domain.<\/p>\n

Siddle K. “Signalling by insulin and IGF receptors: supporting acts and new players.” J Mol Endocrinol.<\/em> 2011. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nIGF-1 LR3 in Cell Culture Applications<\/summary>\n
\n

IGF-1 LR3 is widely used as a serum-free cell culture supplement due to its extended stability and reduced IGFBP sequestration. In 3T3-L1 adipocyte differentiation models, IGF-1 LR3 promoted glucose uptake and GLUT-4 translocation via PI3K-dependent mechanisms. CHO and hybridoma cell cultures showed enhanced proliferation with LR3 supplementation compared to native IGF-1. The extended half-life (approximately 20\u201330 hours vs. 10\u201320 minutes for native IGF-1) reduces required supplementation frequency.<\/p>\n

Tomas FM et al. “IGF-I and especially IGF-I variants are anabolic in dexamethasone-treated rats.” Am J Physiol.<\/em> 1993. PMC<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to IGF-1 LR3 product page Research Library Published research on IGF-1 LR3 \u2014 for educational purposes only IGF-1 LR3 IGFBP Binding Characteristics IGF-1 LR3 has markedly reduced affinity for IGF binding proteins (IGFBPs 1-6), which normally sequester >95% of circulating IGF-1. The Glu\u00b3\u2192Arg\u00b3 substitution disrupts a critical residue in the IGFBP binding domain, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7798","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7798"}],"version-history":[{"count":1,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7798\/revisions"}],"predecessor-version":[{"id":8629,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7798\/revisions\/8629"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}